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LETTERS TO THE EDITOR
Tocainide: Interstitial Pneumonitis
Tocainide is a primary amine analogue of lidocaine with antiarrhyth-
mic properties. Tocainide is indicated for the suppression of symp-
tomatic ventricular arrhythmias, including frequent premature ven-
tricular contractions, unifocal or multifocal, couplets and
nonsustained ventricular tachycardia. This communication draws
attention to an unusual side effect of this drug.
A 76 year old man was seen in the office with productive cough
and wheeziness in the chest. He was a retired coal miner and had
been disabled as a result of occupational pneumoconiosis. He had
been taking tocainide, 400 mg daily with food, for the last 3 months
for the suppression of premature ventricular complexes. Clinically
he was in no respiratory distress but was found to have mild
bronchospasm. Therefore, antibiotic and bronchodilator therapy
was prescribed, but his productive cough did not abate. His symp-
toms gradually progressed to the extent of interfering with his sleep.
chest X-ray film revealed interstitial pneumonitis and peripheral
eosinophilia. Tocainide was discontinued, and the patient was
watched very carefully. Pulmonary status improved with corticoste-
roid therapy over the next 3 days, and repeat chest X-ray examina-
tion showed marked resolution. Serial blood counts showed that
eosinophilia had completely cleared after 7 days. The temporal
relation between the use of tocainide and the presence of pulmonary
eosinophilia suggests a hypersensitivity reaction to the drug.
Review of the literature revealed a case report (I) in which
tocainide-associated interstitial pneumonitis had been described. In
view of this potential adverse reaction, I suggest that the patient
should be instructed to report promptly any development of pulmo-
nary symptoms, such as persistent and severe cough or wheezing.
Although hypersensitivity to tocainide is extremely rare, it
should be considered when a patient taking this drug has pulmonary
symptoms that one cannot explain on a cardiogenic basis. This case
report should heighten clinical awareness.
SAEED AHMAD, MD, FRCP, FACC
Cardio-Diagnostic Clinique
1000 Brookside Drive
Fairmont, West Virginia 26554
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Corrections
Abstracts Withdrawn
Two papers that appeared in abstract form in the Supple-
ment to the February issue of the Journal (J Am ColI Cardiol
©199O by the American College of Cardiology
lACC Vol. 15, No.6
May 1990;1458
1990;15 [suppl A]:60A) were not presented at the 38th
Annual Scientific Session of the American College of Cardi-
ology on March 20, 1990 and have been withdrawn at the
request of the authors. They are: Yee R, Klein GJ, Murdock
C, Leitch JW, Norris C, "Efficacy of antitachycardia pacing
and cardioversion with the pacemaker-cardioverter-
defibrillator" and Fromer M, Schlaepfer J, Goy J-J, Kap-
penberger L, "Initial experience with a new tachyarrhyth-
mia control device."
The paper that appeared in abstract form by Lee JH,
Rosen MR, "Effects of three antiarrhythmic drugs on action
potential characteristics and kinetics of use-dependent block
of canine Purkinje fibers" (J Am ColI Cardiol 1990;[suppl
A]: 126A), had not been accepted for presentation and should
not have appeared in the Supplement. The College apolo-
gizes for this error.
Abstract Not Printed
The following abstract was presented at the 38th Annual
Scientific Session of the American College of Cardiology but
did not appear in the Supplement to the February issue ofthe
Journal.
IN VIVO ASSESSMENT OF THE EFFECT OF ADJACENT SOLID
BOUNDARIES ON THE SIZE OF REGURGITANT JETS BY COLOR
DOPPLER FLOW MAPPING
Chynguang Chen. MD, Leonardo Rodriguez, MD, Gus J
Vlahakes, MD, Luis J. Guerrero, BS, Ajit P. Yoganathan,
PhD, Arthur E. Weyman, MD, FACC, Robert Levine, MD,
FACe, Massachusetts General Hospital, Boston, MA
Recent studies have attempted to predict the severity
of regurgitant (REG) lesions from jet size on Doppler (0)
flow maps. However, in vitro studies have shown that free
jets (FJs) have different jet areas than jets adhering
to flat walls. In order to examine these differences in
vivo with curved surfaces, a canine model of mitral REG
was studied. A fixed orifice inserted into the valve
could be directed to produce FJs or wall jets (WJs) with
identical hemodynamics. Orifices .03-.16 cm2 were used in
7 dogs with peak flow rates of .5-4.3 l/min. Color °flow
was performed in a view parallel to the jet long axis
(LAX) and several perpendicular short axis (SAX) views at
identical imaging settings. RESULTS: 1) In the LAX view,
WJ area was 41 ± 12% less than for FJs at the same flow
rate; maximum jet width Y!EY!' illS. WAl.L
was 36 ± 8% smaller (p < .001, @W~th O.
n • 11); 2) In SAX views, LAX
WJs were splayed around the
left atrium circumference, ~ O~
subtenting a length that was SAX "Q "
greater by 62 ± 18% (p < .001). ~
CONCLUSION In the LAX views (perpendicular to the
walls) most cOl1l11only used .in.....tiY9. for imaging WJs, a
WJ will be smaller than a FJ for the same REG flow: it is
spl ayed around the circumference of the atrium. There-
fore, adjacent walls must be considered in any attempt to
relate jet size to REG volume.
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